Pasar al contenido principal

MODULACION DE RESPUESTA INMUNE EN TRASPLANTE ALOGENICO DE PROGENITORES HEMATOPOYETICOS POR EL GENOTIPO DE MOLECULAS INHIBIDORAS DE CHECKPOINT. BIOBANCO ESPAÑOL DE ALOTPH.

PI17/00815

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INV. DR. JOSEP TRUETA
Centro realización ICO GERONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

  • Cruz, David
  • Rodríguez-Romanos, Rocío
  • González-Bartulos, Marta
  • García-Cadenas, Irene
  • Cámara, Rafael de la
  • Heras, Inmaculada
  • Buño, Ismael
  • Santos, Nazly
  • Lloveras, Natàlia
  • Velarde, Pilar
  • Tuset, Esperanza
  • Martínez, Carmen
  • González, Marcos
  • Sanz, Guillermo F.
  • Ferrá, Christelle
  • Sampol, Antonia
  • Coll, Rosa
  • Pérez-Simón, José A.
  • López-Jiménez, Javier
  • Jurado, Manuel
  • Gallardo, David
  • GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH)
© 2023 Cruz, Rodríguez-Romanos, González-Bartulos, García-Cadenas, de la Cámara, Heras, Buño, Santos, Lloveras, Velarde, Tuset, Martínez, González, Sanz, Ferrá, Sampol, Coll, Pérez-Simón, López-Jiménez, Jurado and Gallardo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Introduction: The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule., Methods: To determine its role in the alloHSCT setting, we analyzed 797 patients transplanted from HLA-identical sibling donors. The LAG3 rs870849 C>T polymorphism was genotyped in donors., Results: We detected a higher incidence of severe acute GVHD in patients transplanted from donors with TT genotype (p: 0.047, HR 1.64; 95% CI 1.01 – 2.67). Overall survival (OS) was worse for patients transplanted from donors with the rs870849 CT/TT genotype (0.020; HR, 1.44; 95% CI 1.06 – 1.96), as well as disease-free survival (DFS) (p: 0.002; HR 1.58, 95%CI: 1.18 – 2.14) and transplant-related mortality (TRM) (p< 0.001; HR: 1.88, 95% CI 1.29 – 2.74). When combining the LAG3 rs870849 and the PDCD1 rs36084323 genotypes of the donor, three genetic groups were well defined, allowing a good stratification of the risk of acute GVHD, TRM, OS and DFS., Discussion: We conclude that the LAG3 genotype of the donor may be considered in donors’ selection. As this selection may be limited in the HLA-identical sibling donor scenario, further studies exploring the impact of LAG3 genotype of the donor in unrelated transplantation are warranted., This work has been financed by grants PI17/00815 and PI20/01353, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

  • Cruz, David
  • Rodríguez-Romanos, Rocío|||0000-0002-2827-7074
  • González-Bartulos, Marta
  • García Cadenas, Irene|||0000-0002-2994-9055
  • de la Camara, Rafael|||0000-0002-8189-5779
  • Heras, Inmaculada
  • Buño, Ismael|||0000-0003-4931-9170
  • Santos, Nazly
  • Lloveras, Natàlia|||0000-0002-9063-2241
  • Velarde, Pilar
  • Tuset, Esperanza|||0000-0002-1463-6689
  • Martínez, Carmen|||0000-0002-8401-7306
  • González, Marcos
  • Sanz, Guillermo F.
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Sampol, Antonia|||0000-0001-7465-6203
  • Coll, Rosa|||0000-0003-0560-1254
  • Pérez-Simón, Jose A.
  • López-Jiménez, Javier
  • Jurado, Manuel|||0000-0001-9156-3797
  • Gallardo, David|||0000-0003-1615-4592
The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule. To determine its role in the alloHSCT setting, we analyzed 797 patients transplanted from HLA-identical sibling donors. The LAG3 rs870849 C.